Member Info for Tommy85

Then consider rival Xtandi (Enzalutamide) ORR of 50% - https://www.cancernetwork.com/view/asco-enzalutamide-monotherapy-prostate-cancer-achieves-high-response-rate-marked-psa-decline

Interesting that support from this study was from Astellas :)

Wouldn't want to be out of this over the weekend, said it hahaha :)

Yes come on Suz, stop ‘dilly’ dallying around and get some news out, like what I did there ;) Really liked this bit from the recent patent update rns ‘ Expanding geographical and scientific protection for these programmes provides a strong commercial background to promote to potential partners’ Let’s turn the screw now! :)

Thinking with the Swedish interest in PQE there is something substantial here. Where could the TOM MCAP be if the 10k bopd was hit? Currently sat at 9m, oil currently at $66 as well :)

Indeed, dived in yesterday through interactive investor, bit of back and forth to place through market best with an additional £49 on top of trade for the AQUIS market, but apart from that all good. Taken a punt as looking forward to seeing what the UK do in regards legalising cannibis production, and will we follow the US like normal :)

Buyluits - a little flock of buys :)

When I saw the RNS preview this morning I thought it was referring to Val 301 haha. Suze doing a little BRR media on the subject https://www.brrmedia.co.uk/broadcasts/602a52921fc46330548f9b04/valirx-extension-of-collaboration-agreement/

In auction???? :)

3 year plan quite interesting, towards the end of presentation.

https://www.valirx.com/news/lsx-presention-1st-5th-february-2021

Adam, you mentioned Val were at the JP Morgan Healthcare event yesterday?

Wouldn't want to be out of this over the weekend hey RB ;) Haha i said it

Iceman, i had a little tickle in ARB last week, to volatile for me and like you topped up VAL shares. Whats next then, 301 with the JAP Pharma or 201 deal? Just hope 201 doesn't take as long as 401!! Haha. HNY all :)

I cant join the webinar in frustration as i am in back to back meetings all afternoon, the beauty of working for Microsoft! Understand the recording will be available after the broadcast, but if someone could pull in some key points of discussion would be most grateful :)

Rapid, professional response from Suzy as always. Looking forward to Tuesday, should be an exciting week :)

Yes of course grace I can pose the question along with how many companies have we got interested in 201 to get a bit of clarity, don’t know if they can answer the latter, but would certainly put the cat amongst the pigeons one would say. Looking forward to your more comprehensive view as you stated yesterday :)

Thank you Grace appreciate the reply. It certainly sets it out in Lehman’s terms and makes it easier for the non scientific individuals such as myself to understand. Good luck with the gold, agree with abc, I have been adding recently in anticipation to news on 201 and 301. I look forward to your long answer as it is valuable and generates good topic of conversation on this bb. ATB :)

Appreciate the reply Adam, many thanks. Don’t know where I got the 16mg from in all honesty as just found the RNS it was just approval from the MHRA To substantially raise the dosing level in patients in order to reach therapeutic levels and reduce disease progression -https://www.lse.co.uk/rns/VAL/re-val201-clinical-trials-nfj1hxnyvd9be2y.html

In my interpretation, to have approval from the MHRA to raise dosing levels is quite spectacular and I wonder if VAL bod keep this in their back pockets when at the deal table :) This with recent results of a 54% ORR among the recent trials will provide even more in the arsenal. Adam another question if you don’t mind, has the MTD been established as of yet? Or will this be in the phase 2b / phase 3 trials with a partner with a larger client test base? Looking forward to Tuesdays webinar also, all moving in the right direction :) ATB

One for Adam / Grace, some time ago the MRHA cleared for 16mg doses of 201, why didn’t Val consider this as an option and only escalate to 8mg in the recent study?

Investor Webcast

ValiRx will host a webcast for investors on Tuesday, 8 December 2020 at 2pm GMT to discuss the findings of the study.



· Prior to the webcast, questions can be submitted online to questions@valirx.com

· During the webcast, questions can be submitted through the webcast link below.



To participate, please click on the link below at the designated time:



https://webcasting.brrmedia.co.uk/broadcast/5fc12476b19325729a9d841f

The webcast will be available on demand following a link on the Company's website after the broadcast. This webcast replaces the usual monthly Q&A publication, and a written summary of questions with answers will be provided after the event.